Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18890998 | 0.86 | PDE5A (0.50) | PDE5ALMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18891204 | 0.84 | TSHR (0.56) | PDE5ALMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL6880703 | 0.78 | KMT2A (0.55) | LMNAHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL18430905 | 0.77 | TSHR (0.55) | PDE5ALMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL22279268 | 0.75 | PDE5A (0.45) | PDE5ALMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL2295550 | 0.75 | KMT2A (0.60) | LMNAHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1230603 | 0.74 | KMT2A (0.56) | LMNAHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5875796 | 0.73 | MEN1 (0.60) | LMNAHTTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL6639187 | 0.73 | KMT2A (0.54) | PDE5ALMNAHTTALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2290641 | 0.73 | KMT2A (0.56) | LMNAHTTALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-10570137-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | TOPADUR PHARMA AG (CH) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169655-A1 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE7A, GNAO1, PDE3A | PDE5A 9/4885LMNA 2511/4885HTT 4356/4885 |
| US-10570137-B2 | 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof | PDE7A, GNAO1, PDE3A | PDE5A 9/4885LMNA 2511/4885HTT 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.